Kodiak Sciences, Nona Biosciences partner on next-gen antibody therapies

The company states: “Nona Biosciences announced a collaboration with Kodiak Sciences (KOD). This partnership aims to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona’s proprietary Harbour Mice fully human antibody platform. The Harbour Mice(R) platform generates fully human monoclonal antibodies in both the two heavy and two light chains format and the heavy chain-only format, eliminating the need for additional engineering or humanization. The HCAb Harbour Mice platform, in particular, is transforming antibody development by producing unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. Under the agreement, Kodiak Sciences gains the right to use both the H2L2 and HCAb Harbour Mice platforms in multiple programs for therapeutic antibody discovery and development.”